SEC FORM 4

SEC FORM 4 SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kynam Global Healthcare Master Fund, LP

(Last)

(First)

(Middle)

C/O OGIER GLOBAL (CAYMAN) LIMITED

89 NEXUS WAY, CAMANA BAY

(Street)

GRAND CAYMAN

KY1-9009

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
2seventy bio, Inc. [ TSVT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

Director	X	10% Owner
Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/10/2023

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock, par value $0.0001 per share	08/10/2023		P		179,000	A	$5.94	5,703,825	I	See Footnote⁽¹⁾
Common Stock, par value $0.0001 per share	08/10/2023		P		50,000	A	$5.8	5,753,825	I	See Footnote⁽¹⁾
Common Stock, par value $0.0001 per share	08/10/2023		P		100,000	A	$5.85	5,853,825	I	See Footnote⁽¹⁾
Common Stock, par value $0.0001 per share	08/10/2023		P		100,000	A	$5.96	5,953,825	I	See Footnote⁽¹⁾
Common Stock, par value $0.0001 per share	08/10/2023		P		86,414	A	$5.96	5,142,111	D⁽²⁾
Common Stock, par value $0.0001 per share	08/10/2023		P		86,414	A	$5.96	5,142,111	I	See Footnote⁽³⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

1. Name and Address of Reporting Person^*

Kynam Global Healthcare Master Fund, LP

(Last)

(First)

(Middle)

C/O OGIER GLOBAL (CAYMAN) LIMITED

89 NEXUS WAY, CAMANA BAY

(Street)

GRAND CAYMAN

KY1-9009

(City)

(State)

(Zip)

1. Name and Address of Reporting Person^*

Kynam Fund GP, LLC

(Last)

(First)

(Middle)

221 ELM ROAD

(Street)

PRINCETON

08540

(City)

(State)

(Zip)

1. Name and Address of Reporting Person^*

Kynam Capital Management GP, LLC

(Last)

(First)

(Middle)

221 ELM ROAD

(Street)

PRINCETON

08540

(City)

(State)

(Zip)

1. Name and Address of Reporting Person^*

Tang Yue

(Last)

(First)

(Middle)

C/O KYNAM CAPITAL MANAGEMENT, LP

221 ELM ROAD

(Street)

PRINCETON

08540

(City)

(State)

(Zip)

Explanation of Responses:

1. The reported securities are owned directly by Kynam Global Healthcare Master Fund, LP (the "Master Fund"), a private investment fund managed by Kynam Capital Management, LP (the "Adviser"), and separately managed account clients of the Adviser and may be deemed to be indirectly beneficially owned by (i) the Adviser, (ii) Kynam Capital Management GP, LLC (the "Adviser GP"), the general partner of the Adviser and (iii) Yue Tang, the managing member of the Adviser GP. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

2. The reported securities are directly owned by the Master Fund. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

3. The reported securities are owned directly by the Master Fund and may be deemed to be indirectly beneficially owned by Kynam Fund GP, LLC, the general partner of the Master Fund. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Remarks:

Reference is made to the Form 4 filed by the Reporting Persons on August 14, 2023.

	KYNAM GLOBAL HEALTHCARE MASTER FUND, LP, By: KYNAM FUND GP, LLC, By: /s/ Yue Tang, Yue Tang, Managing Member	08/16/2023
	KYNAM FUND GP, LLC, By: /s/ Yue Tang, Yue Tang, Managing Member	08/16/2023
	KYNAM CAPITAL MANAGEMENT GP, LLC, By: /s/ Yue Tang, Yue Tang, Managing Member	08/16/2023
	YUE TANG, /s/ Yue Tang	08/16/2023
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

SEC Form 4: Kynam Global Healthcare Master Fund, Lp bought $3,564,315 worth of shares (601,828 units at $5.92)